Date: 2011-02-28
Type of information: R&D agreement
Compound: HEMARINA-M101 (HEMOXYcarrier®)
Company: Hemarina (France) U.S. Naval Medical Research Center (USA)
Therapeutic area: Traumatology - CNS diseases
Type agreement: R&D
Action mechanism: Hemoglobin Oxygen Carrier
Disease: traumatic brain injury
Details: Hemarina has recently entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center for the use of HEMOxycarrier®, the last generation of universal oxygen carrier. This CRADA is titled, Advancing Oxygen Therapeutic Agent development by evaluating the vasoactivity, oxygen carrying capacity, and effectiveness of HEMARINA-M101 (HEMOXYcarrier®) in a non clinical model as a pre hospital resuscitation fluid for traumatic brain injury, with or without hemorrhagic shock. This is a three-year study that will test the HEMOXYcarrier® on laboratory models.This research responds to the identified medical need to improve pre-hospital aid of traumatic brain injury (TBI), which may be complicated by hemorrhagic shock (HS), by evaluation novel oxygen therapeutics that may reduce neurological damage in the immediate post-injury phase. This novel generation of oxygen therapeutic agent should be screened for potential use. Therefore, a screening survey is proposed to evaluate HEMOXYcarrier® for pre-hospital use in combat casualties with TBI/HS. The overall objective of this research agreement is the evaluation of the HEMOXYcarrier® product in the prehospital setting for casualties with polytrauma TBI/HS.
Financial terms: Financial terms were not disclosed.
Latest news:
